Last updated: 2026-10-01 18:56:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
CalciMedica, Inc. (CALC) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.69, with a market capitalisation of $10.99M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.58 to $36.00. This page covers its latest market performance, valuation, price trends and company information.
$10.99M | |
$1.62 | |
$2,807.00 | |
$1.58 | |
$1.62 | |
17.94K | |
75.39K | |
-- | |
$36.00 | |
$1.58 | |
-- | |
-- |
CalciMedica, Inc. (CALC) is currently trading at $1.69 as of 2026-10-01 18:55:00, up 4.32% ($0.07) from the previous close of $1.62
During today's regular trading session, CALC has traded between $1.58 and $2,807.00, with a trading volume of 17.94K shares. The current price is near the lower end of today's range.
Over the past seven days, CalciMedica, Inc. (CALC) moved from $1.87 to $1.69, representing a decline of 9.63% ($0.18).
The stock traded between $1.58 and $1.98 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 53.07 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.3%
CALC is currently trading at $1.69, placing it 0.3% of the way from its 52-week low of $1.58 to its 52-week high of $36.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 15 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CalciMedica, Inc. (CALC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.